GB2394658A — Oral anti-cancer composition
Assigned to Cancer Research Technology Ltd · Expires 2004-05-05 · 22y expired
What this patent protects
The present invention relates to the use of the compounds of formula I <SL> <LI>where (a) R4 and R5 with the C atoms to which they are attached form a 6-membered aromatic ring having substituents -B-COOH (where B is a hydrocarbyl link) and R3 and R1, R2 and R3 are sta…
USPTO Abstract
The present invention relates to the use of the compounds of formula I <SL> <LI>where (a) R4 and R5 with the C atoms to which they are attached form a 6-membered aromatic ring having substituents -B-COOH (where B is a hydrocarbyl link) and R3 and R1, R2 and R3 are standard substituents <LI>or (b) each of R4 and R5 is H or optionally substituent phenyl with the proviso only one is H, R1 is H, alkyl or alkoxy and R2 is B-COOH as above. </SL> A preferred compound is 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The compounds are for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compositions, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.